Neal Walker

CIK: 0001604457

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)13 (37.1%)

Derivative conversions

Awards (A)9 (25.7%)

Compensation grants

Other (G, F, J, C, D, …)13 (37.1%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (2)

ALDX

Aldeyra Therapeutics, Inc.

Director

ACRS

Aclaris Therapeutics, Inc.

DirectorOfficer

Discretionary Trading P&L

Holdings

Transaction History (35 total)

ALDX
Aldeyra Therapeutics, Inc.
Jun 9, 2026
Award(A)
Stock Option (Right to Buy)
Direct
3.3K shares-
ALDX
Aldeyra Therapeutics, Inc.
Jun 9, 2026
Award(A)
Stock Option (Right to Buy)
Direct
70K shares-
ACRS
Aclaris Therapeutics, Inc.
Feb 3, 2026
Exercise(M)
Direct
63.5K shares-
ACRS
Aclaris Therapeutics, Inc.
Feb 3, 2026
Tax Payment(F)
Direct
18.6K shares at avg. $3.47$65K
ACRS
Aclaris Therapeutics, Inc.
Feb 2, 2026
Award(A)
Employee Stock Option (Right to Buy)
Direct
961.7K shares-
ACRS
Aclaris Therapeutics, Inc.
Feb 2, 2026
Award(A)
Restricted Stock Units
Direct
274.8K shares-
ACRS
Aclaris Therapeutics, Inc.
Jan 2, 2026
Exercise(M)
Direct
29.2K shares-
ACRS
Aclaris Therapeutics, Inc.
Jan 2, 2026
Tax Payment(F)
Direct
10K shares at avg. $2.88$29K
ALDX
Aldeyra Therapeutics, Inc.
Jun 10, 2025
Award(A)
Stock Option (Right to Buy)
Direct
62.7K shares-
ALDX
Aldeyra Therapeutics, Inc.
Jun 10, 2025
Award(A)
Stock Option (Right to Buy)
Direct
2.4K shares-
ACRS
Aclaris Therapeutics, Inc.
May 1, 2025
Tax Payment(F)
Direct
3K shares at avg. $1.38$4K
ACRS
Aclaris Therapeutics, Inc.
May 1, 2025
Exercise(M)
Direct
9.5K shares-
ACRS
Aclaris Therapeutics, Inc.
Apr 1, 2025
Tax Payment(F)
Direct
3K shares at avg. $1.48$5K
ACRS
Aclaris Therapeutics, Inc.
Apr 1, 2025
Exercise(M)
Direct
9.5K shares-
ACRS
Aclaris Therapeutics, Inc.
Mar 1, 2025
Exercise(M)
Direct
9.5K shares-
ACRS
Aclaris Therapeutics, Inc.
Mar 1, 2025
Tax Payment(F)
Direct
3.3K shares at avg. $1.99$7K
ACRS
Aclaris Therapeutics, Inc.
Feb 3, 2025
Award(A)
Employee Stock Option (Right to Buy)
Direct
888.8K shares-
ACRS
Aclaris Therapeutics, Inc.
Feb 3, 2025
Award(A)
Restricted Stock Units
Direct
253.9K shares-
ACRS
Aclaris Therapeutics, Inc.
Feb 1, 2025
Tax Payment(F)
Direct
3.6K shares at avg. $2.48$9K
ACRS
Aclaris Therapeutics, Inc.
Feb 1, 2025
Exercise(M)
Direct
9.5K shares-
ACRS
Aclaris Therapeutics, Inc.
Jan 2, 2025
Exercise(M)
Direct
29.1K shares-
ACRS
Aclaris Therapeutics, Inc.
Jan 2, 2025
Tax Payment(F)
Direct
13.5K shares at avg. $2.48$34K
ACRS
Aclaris Therapeutics, Inc.
Jan 2, 2025
Award(A)
Restricted Stock Units
Direct
88.3K shares-
ACRS
Aclaris Therapeutics, Inc.
Jan 1, 2025
Exercise(M)
Direct
9.5K shares-
ACRS
Aclaris Therapeutics, Inc.
Jan 1, 2025
Tax Payment(F)
Direct
3.9K shares at avg. $2.48$10K

		Type	Shares	Price		Ownership
Jun 9, 2026	ALDX Aldeyra Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	3,318	-	-	Direct
Jun 9, 2026	ALDX Aldeyra Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	70,000	-	-	Direct
Feb 3, 2026	ACRS Aclaris Therapeutics, Inc.	Exercise(M)	63,475	-	$0	Direct
Feb 3, 2026	ACRS Aclaris Therapeutics, Inc.	Tax Payment(F)	18,611	$3.47	$64,580	Direct
Feb 2, 2026	ACRS Aclaris Therapeutics, Inc.	Award(A) Employee Stock Option (Right to Buy)	961,700	-	-	Direct
Feb 2, 2026	ACRS Aclaris Therapeutics, Inc.	Award(A) Restricted Stock Units	274,800	-	-	Direct
Jan 2, 2026	ACRS Aclaris Therapeutics, Inc.	Exercise(M)	29,150	-	$0	Direct
Jan 2, 2026	ACRS Aclaris Therapeutics, Inc.	Tax Payment(F)	9,952	$2.88	$28,662	Direct
Jun 10, 2025	ALDX Aldeyra Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	62,728	-	-	Direct
Jun 10, 2025	ALDX Aldeyra Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	2,413	-	-	Direct
May 1, 2025	ACRS Aclaris Therapeutics, Inc.	Tax Payment(F)	2,975	$1.38	$4,106	Direct
May 1, 2025	ACRS Aclaris Therapeutics, Inc.	Exercise(M)	9,467	-	-	Direct
Apr 1, 2025	ACRS Aclaris Therapeutics, Inc.	Tax Payment(F)	3,042	$1.48	$4,502	Direct
Apr 1, 2025	ACRS Aclaris Therapeutics, Inc.	Exercise(M)	9,467	-	-	Direct
Mar 1, 2025	ACRS Aclaris Therapeutics, Inc.	Exercise(M)	9,466	-	-	Direct
Mar 1, 2025	ACRS Aclaris Therapeutics, Inc.	Tax Payment(F)	3,277	$1.99	$6,521	Direct
Feb 3, 2025	ACRS Aclaris Therapeutics, Inc.	Award(A) Employee Stock Option (Right to Buy)	888,800	-	-	Direct
Feb 3, 2025	ACRS Aclaris Therapeutics, Inc.	Award(A) Restricted Stock Units	253,900	-	-	Direct
Feb 1, 2025	ACRS Aclaris Therapeutics, Inc.	Tax Payment(F)	3,559	$2.48	$8,826	Direct
Feb 1, 2025	ACRS Aclaris Therapeutics, Inc.	Exercise(M)	9,467	-	-	Direct
Jan 2, 2025	ACRS Aclaris Therapeutics, Inc.	Exercise(M)	29,149	-	$0	Direct
Jan 2, 2025	ACRS Aclaris Therapeutics, Inc.	Tax Payment(F)	13,532	$2.48	$33,559	Direct
Jan 2, 2025	ACRS Aclaris Therapeutics, Inc.	Award(A) Restricted Stock Units	88,333	-	-	Direct
Jan 1, 2025	ACRS Aclaris Therapeutics, Inc.	Exercise(M)	9,467	-	$0	Direct
Jan 1, 2025	ACRS Aclaris Therapeutics, Inc.	Tax Payment(F)	3,904	$2.48	$9,682	Direct

1-25 of 35 transactions

About Walker Neal

Walker Neal (SEC CIK 0001604457) files insider reports with the SEC as Director of Aldeyra Therapeutics, Inc. (ALDX) and CEO of Aclaris Therapeutics, Inc. (ACRS).

Signal8 holds 15 ownership filings by Walker Neal, all Form 4s, filed between Sep 4, 2024 and Jun 11, 2026. Those filings report 35 transactions, from Sep 1, 2024 to Jun 9, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Walker Neal's filings is in LEXINGTON, MA.

Recent filings by Walker Neal

Jun 9, 2026: Grants or awards of ALDX derivative securities (2 lines, Form 4, code A).
Feb 3, 2026: Option exercise of ACRS shares (Form 4, code M).
Feb 3, 2026: Tax withholding of ACRS shares (Form 4, code F).
Feb 2, 2026: Grants or awards of ACRS derivative securities (2 lines, Form 4, code A).
Jan 2, 2026: Option exercise of ACRS shares (Form 4, code M).

Other insiders filing for Aldeyra Therapeutics, Inc. (ALDX)

How to read Form 4 transaction codes